Introduction:

the biomodulin T has cyto-restorative and immunomodulatory action by stimulating lymphoblastoid mitosis, in that way the differentiation of T-lymphocytes is normalized; in models of acute inflammation, edema and chronic inflammation showed an anti-inflammatory effect by modulating the induced inflammatory response.

Objective:

to evaluate the therapeutic response of biomodulin T in susceptible patients to SARS-CoV-2.

Methods:

a descriptive, prospective longitudinal study was carried out at the Immunology Clinic from “Arnaldo Milián Castro” Hospital, in Villa Clara Province, from March 2020 to September 2020. A total of 52 patients who presented personal pathological antecedents that made them susceptible to suffer from SARS CoV-2 virus infection were studied.

Results:

descriptive statistical methods such as frequency tables for the variables age, sex, personal pathological history and response to treatment with biomodulin T were applied. The age group with the most comorbidities was 40 to 59 years, male sex predominated and most patients had a history of chronic obstructive pulmonary disease, diabetes mellitus and arterial hypertension. The largest number of patients had a diagnosis of autoimmune diseases.

Conclusions:

the therapeutic response was satisfactory for all age groups.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )